Isolpharm

ISOLPHARM 2024 annual meeting

On December 12th, the ISOLPHARM 2024 annual meeting took place at the Legnaro National Laboratories of INFN. The Work Packages of the ADMIRAL and ISOLPHARM_CORE experiments showed their latest results[…]

3D Experiment Updates: Exciting New Results!

The 3D scaffold bioprinting experiments for the ISOLPHARM project started at the beginning of 2024 with some geometry printing tests, where GelMa was cured under a DLP homemade printer with[…]

First clonogenic assay using silver-111

In October 2024, the ISOLPHARM collaboration successfully performed the first clonogenic survival evaluation using silver-111 on cancer cells. In particular, the UMR-106 rat osteosarcoma cell line was tested. This result[…]

A Large Collaboration Between Universities and Research Centers

The ISOLPHARM Project was born from the collaboration between the Departments of Pharmaceutical and Pharmacological, Department of Chemical Sciences of the University of Padova and the Legnaro National Laboratories (LNL) of the National Institute of Nuclear Physics (INFN) where the Selective Production of Exotic Specie (SPES) project in under development. By means, of Isotope Separation On-Line technique both traditional and innovative radioisotopes will be produced with high-specific activity, going beyond the state-of-art of the radioisotope production.

Strengths and key features

The key features of ISOLPHARM are: a) the presence of a strong local collaboration between INFN-LNL, INFN-PD, INFN-PV, TIFPA, UNIPD and UNIBS in many fields of research, ranging from the production of the RIBs to the employment of the radionuclides. b) the ISOL technique, which can easily provide high specific activity radionuclides. c) the INFN patent, which proves the innovation and excellence of the project. d) the low environmental and social impact, since nuclear reactors are not used for the provision of the radionuclides, which traditionally may be obtained irradiating massive amount of materials, that lately become tons of nuclear wastes.